The Optimizing Innovation, Commercialization and Entrepreneurship of Biomedical Research program of the CCTS in partnership with the Corporate Engagement Office and Nationwide Children’s Hospital’s Office of Technology Commercialization is launching a new Panel Speaker Series in response to the urgent need for academic innovations to combat the global pandemic. This series will feature some of the work happening on our campuses at an unprecedented pace on the front lines of innovation.
The novel coronavirus, SARS-CoV-2, behind the global pandemic has killed over 400,000 people, with the toll rising by thousands every day. Combating the virus, which causes a highly contagious infection, COVID-19, has dramatically reshaped and galvanized the innovation ecosystem spurring an unprecedented rate of innovation. There is still plenty of work to do. At a conference on June 9, 2020, Tedros Adhanom Ghebreyesus, Director-General of the World Health, said, “More than six months into this pandemic, this is not the time for any country to take its foot off the pedal. This is the time for countries to continue to work hard.”
To inspire ongoing innovations and collaborations in the fight against COVID-19, the new Monthly Speaker Series aims to promote an entrepreneurial mindset among clinicians, faculty, senior leaders, students and staff of The Ohio State University and Nationwide Children’s Hospital. Since academic entrepreneurship is a team sport, the series will provide a forum for showcasing COVID-19 innovations as well as key resources in the innovation ecosystem.
Some of the goals of the new series are to:
- Showcase unprecedented innovations, collaborations and private-public partnerships developed in the fight against the pandemic
- Feature inventors from a variety of fields and their exemplary work at the intersection of academic achievement, science, technology, and business in the fight against COVID-19.
- Animate entrepreneurship as an exciting pathway and outcome of university research to address the most urgent and critical health challenge of our time.
- Demystify and nurture an entrepreneurial mindset among our clinicians, faculty and students
- Introduce and bring together representatives from the various support services, resources, funding mechanisms, training and guidance available to inventors
- Inspire new innovation teams to address various aspects of the pandemic from discovery to prevention to therapies.
The panel speaker series will be offered once a month and only through a virtual platform.
There will be time for Q&A following the panel discussions. All are welcome.
July COVID-19 Inventor Showcase: Enhancing Innate COVID-19 Immunity
The race to find a cure for COVID-19 began on January 10, 2020 when the Chinese government released the genetic sequence of the virus – SARS-CoV-2 – responsible for the global pandemic of an extremely spreadable and potentially fatal disease. Researchers around the world began to build bits of the virus in their labs to develop therapies, with the aim of making us immune. Now, after 500,000 deaths, WHO warns worst of coronavirus pandemic is “yet to come”. Although most of the COVID-19 patients have mild or moderate courses, up to 5%–10% can have severe, potentially life threatening course – hence, the urgent need for effective drugs. Join us to learn how researchers at Nationwide Children’s Hospital developed a method for generating large numbers of clinical-grade Natural Killer (NK) cells for cancer therapy which has the potential to augment the innate immunity of high-risk patients with mild or moderate COVID-19 disease and to prevent progression to severe COVID-19 disease.
Date: July 14, 2020, Tuesday, 12 noon to 1 p.m. EST
July COVID-19 Inventor Team
• Chris P. Ouellette, MD, Section of Infectious Diseases and Host Defense Program at Nationwide Children’s Hospital and Assistant professor of Pediatrics at The Ohio State University College of Medicine.
• Dean Anthony Lee, MD, PhD, Division of Hematology and Oncology at Nationwide Children’s Hospital and Professor of Pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy.
July Innovation Resource Team
- Nationwide Children’s Hospital Drug and Device Development Services: Kevin Bosse, PhD, RAC
- Nationwide Children’s Hospital Host Defense Program: Christopher P. Ouellette, MD
- Nationwide Children’s Hospital Cellular Therapy and Cancer Immunology Program: Margaret Lamb, MD
- OSU/NCH Campus GMP Facilities for Cell Therapy Manufacturing: Dean Lee, MD, PhD